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SUMMARY 
Serotonin-producing neurons profusely innervate brain regions via long-range projections. 
However, it remains unclear whether and how endogenous serotonergic transmission specifically 
influences regional or global functional activity. We combined DREADD-based chemogenetics and 
fMRI, an approach we term “chemo-fMRI”, to causally probe the brainwide substrates modulated 
by endogenous serotonergic activity. We describe the generation of a conditional knock-in mouse 
line that, crossed with serotonin-specific Cre-recombinase mice, allowed us to remotely stimulate 
serotonergic neurons during fMRI scans. We show that endogenous stimulation of serotonin-
producing neurons does not affect global brain activity, but results in region-specific activation of a 
set of primary target regions encompassing cortico-hippocampal and ventro-striatal areas. By 
contrast, pharmacological boosting of serotonin levels produced widespread fMRI deactivation, 
plausibly reflecting the mixed contribution of central and perivascular constrictive effects. Our 
results identify the primary functional targets of endogenous serotonergic stimulation, and 
establish causation between activation of serotonergic neurons and regional fMRI signals. 
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Introduction 
Serotonin (5-HT) is a modulatory transmitter produced by a small set of midbrain and brainstem 
nuclei that richly innervate forebrain target regions via long-range projections (Maddaloni et al., 
2017). Such profuse innervation, along with the combined release of transmitters via pointwise 
synaptic signalling as well as non-synaptic ‘volume transmission’ (Descarries and Mechawar, 2000), 
can alter neuronal functions to define internal states that affect behavioural outputs in response to 
external stimuli. Recent research has shed light on the basic cellular and molecular machinery 
engaged by 5-HT (Lesch and Waider, 2012). However, many questions regarding the systems-level 
substrates modulated by 5-HT transmission remain unanswered. For one, it is unclear whether 
serotonin’s modulatory action entails a global regulation of neural activity, or it is relayed and 
encoded by a set of primary functional targets. 
Neuroimaging studies have employed pharmacological manipulations to probe the 
brainwide targets of 5-HT. The vast majority of these studies have primarily focused on the use of 
functional magnetic resonance imaging (fMRI) as a proxy for the neuronal activity directly elicited 
by pharmacological agents, or by mapping second-order modulatory effects on task-elicited fMRI 
responses (Anderson et al., 2008). This approach, termed pharmacological fMRI, has also been 
back-translated to animal studies (Klomp et al., 2012). However, while useful in identifying possible 
brainwide substrates of neuromodulatory action, drug-based approaches are often contaminated 
by off-target receptor contributions (Ofek et al., 2012), and often contain peripheral vasotonic or 
cerebrovascular contributions that cannot be easily disentangled from the drug’s primary neural 
effects (Martin and Sibson, 2008). This aspect is especially relevant when hemodynamic measures 
of brain function are used, given that 5-HT can perivascularly modulate blood flow, independent of 
its central effects (Cohen et al., 1996). As a result, it remains unclear where and how endogenous 
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serotonergic activity specifically influences regional or global brain functional activity, and the 
corresponding fMRI responses. 
Light-based or chemically-mediated cell-manipulations have made it possible to causally link 
the activity of focal neuronal populations with specific circuital and behavioural outputs (Park and 
Carmel, 2016). When combined with non-invasive neuroimaging methods, cell-type specific 
manipulations can be used to map the functional substrates of endogenous modulatory 
transmission, without the confounding contribution of peripherally-elicited vasoactive or 
pharmacological effects. Towards this goal, here we describe the combined use of mouse cerebral-
blood volume based fMRI (rCBV, Galbusera et al., 2017) and cell-type specific DREADD (Designed 
Receptors Exclusively Activated by Designed Drugs,  Armbruster et al., 2007)) chemogenetics, an 
approach we term ‘chemo-fMRI’, to map the brainwide functional targets of sustained 5-HT 
stimulation. 
To allow for stable and reproducible endogenous 5-HT stimulation across animals we 
generated a conditional knock-in mouse that we crossed with Pet1-Cre transgenic mice (Pelosi et 
al., 2014), endowing 5-HT specificity (Spencer and Deneris, 2017). This approach allowed us to 
remotely stimulate 5-HT-producing neurons during fMRI scans, with reduced inter-subject 
variability. Our results show that chemogenetic 5-HT stimulations do not affect global brain activity, 
but results in region specific activation of a set of primary target regions encompassing cortico-
hippocampal, and midbrain structures, as well as components of the mesolimbic reward systems. 
Notably, pharmacological boosting of 5-HT level via systemic administration of the 5-HT reuptake 
inhibitor citalopram produced widespread fMRI deactivation, plausibly reflecting the mixed 
contribution of central and perivascular constrictive effects. Collectively, our results reveal a set of 
regional substrates that act as primary functional targets of endogenous serotonergic stimulation 
and establish causation between endogenous activation of 5-HT neurons and regional fMRI signals. 
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They also provide a novel framework for understanding 5-HT-dependent functions and interpreting 
data obtained from human fMRI studies of 5-HT modulating agents. 
. 
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Results 
hM3Dq-mediated modulation of serotonergic neurons  
To enable stable pan-neuronal stimulation of 5-HT producing cells, we first generated a hM3Dq 
conditional knock-in mouse encompassing the integration of hM3Dq-mCherry double-floxed 
inverse open reading frame (DIO-hM3Dq) within the ROSA26 genomic locus (Fig. 1). In the designed 
mouse line, stable Cre-mediated somatic recombination is required for conditional transcriptional 
activation (CAG promoter-driven) of the hM3Dq gene, whose expression could be probed by the 
presence of in-frame-fused mCherry reporter (Fig. 1). To enable hM3Dq expression in 5-HT 
producing neurons, DIO-hM3Dq mice were crossed with the Pet1210-Cre transgenic mouse line 
(Pelosi et al., 2014). Immunofluorescence analysis on double trans-heterozygous hM3Dq/Pet1-Cre 
mice revealed that hM3Dq is expressed in the vast majority (95.9%) of 5-HT producing neurons (Fig. 
2A-D’). 
We next recorded the electrophysiological response induced by CNO administration in 
hM3Dq-expressing 5-HT neurons via whole-cell patch clamp recordings in the dorsal raphe nucleus 
(DRN). mCherry-positive neurons in hM3Dq/Pet1-Cre mice were robustly activated by CNO, 
resulting in sustained firing rates (Fig. 2E). We did not observe any CNO-induced firing rate 
alterations in any of the neighboring mCherry-negative neurons probed, or in 5-HT neurons in DIO-
hM3Dq control mice (Fig. 2F-G).  
Chemo-fMRI mapping of endogenous 5-HT neurotransmission  
To control for possible off-target effects of CNO and its metabolites, we first performed a dose-
response titration of the fMRI response produced by CNO in wild-type mice (Fig. S1). Intravenous 
CNO administration at doses of 1 and 2 mg/kg produced significant rCBV increases in most of the 
examined regions (Fig. S1, p<0.05, corrected at q=0.05). Upon intravenous dosing of CNO at 0.5 
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mg/kg the rCBV signal was qualitatively distinguishable from reference baseline signal only in 
hypothalamic and hippocampal areas, and no statistically significant alterations was detected in 
regional or voxelwise quantifications with respect to vehicle (p>0.42, Z>1.6 in voxelwise maps). 
Pharmacokinetic profiling of this dose (Fig. S1-C) revealed sustained plasma CNO exposure 
throughout the imaging time-window, plus the presence of low but detectable levels of clozapine. 
The observed peak exposure of clozapine (8±6 ng/ml) is ~25-fold lower than behaviorally-relevant 
plasma levels of this compound in rodents (Olsen et al., 2008), and below the range of values 
previously associated with detectable brain exposure (Volpicelli et al., 1993). Based on these 
assessments, we chose to perform subsequent chemogenetic-fMRI mapping using an i.v. dose of 
0.5 mg/kg. As a further control for possible CNO/clozapine off-target effects, fMRI mapping and all 
the supporting experiments were performed ad quantified by administering CNO to both 
hM3Dq/Pet1-Cre and control DIO-hM3Dq reference mice. CNO administration did not alter 
peripheral blood pressure at any of dose tested (Fig. S2) 
Chemogenetic activation of 5-HT producing neurons elicited robust rCBV increases in several 
cortical and non-cortical substrates in hM3Dq/Pet1-Cre mice (Fig. 3, Z>2, cluster corrected p=0.05, 
Fig. S3). The elicited chemo-fMRI response encompassed parietal cortical and motor cortices, as 
well as posterior insular and temporal association regions, plus several subcortical substrates, 
including hippocampal areas, the hypothalamus, the dorsal raphe and cerebellum. A prominent 
involvement of ventral tegmental area and its mesolimbic terminals in the nucleus accumbens was 
also apparent.  
To probe a neural origin of hM3Dq-mediated fMRI response, we performed local field 
potential (LFP) measurements in the dorsal hippocampus of halothane-anesthetized animals 
(Galbusera et al., 2017). CNO administration (0.5 mg/kg i.v.) produced significant LFP power 
increases in the theta (F1,22=110.2 p<0.001) and gamma bands (F1,22=239.4 p<0.001) in 
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hM3Dq/Pet1-Cre, but not in DIO-M3Dq control animals (Fig. S4). To rule out an interaction between 
the anesthesia used for fMRI and 5-HT chemogenetic manipulations, we carried out c-Fos 
immunofluorescence mapping in unanesthetized mice upon intraperitoneal administration of 2 
mg/kg of CNO (see dose selection in Supplemental Experimental Procedures). This dosing strategy 
does not elicit substantial fMRI signal alterations (Fig. S5, p>0.26 all regions). We observed robust 
and recognizable increases in c-Fos positive neurons in many regional substrates identified with 
fMRI, including the nucleus accumbens, hippocampus, anterior thalamus, hypothalamic nuclei and 
raphe nuclei (Fig. S6 A-E, p<0.05, all regions, q=0.05). No inter-group differences were observed in 
somatosensory cortex (Fig. S6 A-E), while no detectable c-Fos reactivity was observed in the 
cerebellum in either CNO-treated group (data not shown). The same dose of CNO (2 mg/kg i.p.) 
elicited significant release of extracellular serotonin in hM3Dq/Pet1-Cre, but not in DIO-M3Dq 
control animals as assessed with hippocampal microdialysis in unanesthetized animals (Fig S6-F, 
F1,10=7.76, p=0.02). 
Systemic 5-HT reuptake inhibition produces fMRI deactivation  
An underlying assumption of our work is that the signals elicited by CNO in hM3Dq/Pet1-Cre mice 
primarily reflect central 5-HT neuronal stimulation, which in turns elicits rCBV changes via 
neurovascular and neurometabolic coupling. By contrast, fMRI mapping of systemically-
administered 5-HT ligands may be contaminated or masked by direct stimulation of endothelial 5-
HT receptors, which produces vasoconstrictive responses (Cohen et al., 1996). To compare the 
effect of endogenous versus systemic pharmacological 5-HT stimulation, we carried out fMRI 
mapping upon administration of the selective 5-HT reuptake inhibitor citalopram (5-10 mg/kg), a 
drug leading to increased central and circulating 5-HT levels (Blardi et al., 2005). Interestingly, 
citalopram (10mg/kg i.v.) produced widespread foci of rCBV signal decrease in a widespread set of 
cortical and subcortical regions, as seen with voxelwise mapping (Fig. S7, Z >1.8, cluster corrected 
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p=0.05). Although the effect was widely distributed, the deactivation was particularly prominent in 
the prefrontal cortex (Fig. 4B, Fig. S7). Citalopram administration was not associated with 
appreciable blood pressure alteration at any of the doses tested (Fig. S2).  
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Discussion  
Serotonin is an archetypical neuromodulatory monoamine characterized by broad and far-ranging 
modulatory properties. Despite extensive research, the macroscale functional substrates 
endogenously modulated by 5-HT in the intact brain remain elusive. By using chemo-fMRI, we 
describe the primary brainwide targets of sustained serotonergic stimulation, and establish 
causation between endogenous activation of 5-HT neurons and regional fMRI signals. Our results 
provide a novel framework for understanding 5-HT-dependent function and interpreting data 
obtained from human fMRI studies of 5-HT modulatory agents. 
While the density of 5-HT ascending projection is highly variable across neuroanatomical 
regions, virtually no area in the central nervous system is devoid of 5-HT innervation (Maddaloni et 
al., 2017). Our observation of region-specific responses in spite of the use of drug-like pan-
serotonergic stimulation provides evidence that endogenous 5-HT neurotransmission engages a set 
of neuroanatomical targets that serve as primary, fast-responding effectors of sustained release of 
this neurotransmitter. This notion is consistent with a role of 5-HT as a mediator of arousal (Lee and 
Dan, 2012), and species-normative consummatory behaviours that strongly engage evolutionary-
ancient ventro-limbic substrates (Takahashi et al., 2012, Liu et al., 2014). The presence of parieto-
cortical activation is in keeping with the result of metabolic and cerebral blood flow mapping upon 
electrical or chemical stimulation of raphe regions (Cohen et al., 1996, Underwood et al., 1995). 
While the robust activation of hippocampal, hypothalamic, and midbrain areas is consistent with 
the especially dense 5-HT innervation of these areas, qualitative comparisons with prior fiber or 5-
HT terminal density quantifications (Willoughby and Blessing, 1987, Maddaloni et al., 2017) do not 
support a regional relationship between rCBV activation and 5-HT innervation density. Different 5-
HT signaling properties, such as a differential contribution of wiring and volume transmission 
(Descarries and Mechawar, 2000), as well as regional combinations of receptor subtypes 
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characterized by different transductional pathways or cellular distribution may underlie the 
selective functional engagement observed with endogenous 5-HT stimulation. Importantly, our 
mapping provides functional evidence that serotonergic activation can also modulate the activity of 
mesolimbic dopaminergic areas such as the nucleus accumbens. This finding underscores a 
functional interplay between these two key modulatory systems, and supports the emerging view 
of a role of 5-HT as a possible modulator of reward processing and mesolimbic dopaminergic 
substrates (Li et al., 2016, Luo et al., 2015). A mechanistic contribution of promiscuous 
monoaminergic transport could also play a role in the mapped activation, as suggested by recent 
molecular imaging studies (Hai et al., 2016, Zhou et al., 2005).  
Interestingly, recent mapping of chemogenetically-stimulated neurons via 2-fluoro-dexoy-
glucose PET did not highlight cortico-hippocampal modulation of brain activity, but revealed small 
foci of reduced metabolism in thalamic areas (Urban et al., 2016). Several experimental factors 
could account for these discrepant results, including the use of deep anaesthesia vs. light sedation, 
and the possible contribution of unspecific effects of CNO, given that Urban et al., did not employ a 
CNO-treated group as a baseline reference for brain mapping. This aspect is of especial importance 
in the light of a recent report pointing at a possible role of converted clozapine as primary effector 
of DREADD-induced manipulations (Gomez et al., 2017). Our pharmacokinetic data are consistent 
with this view, showing that CNO can be converted to clozapine in vivo. However, several lines of 
evidence argue against a significant off-target contribution of converted clozapine to our mapping. 
First, our chemo-fMRI mapping was performed at CNO doses that negligibly affect fMRI signals. 
Second, we have quantified and described all chemogenetic responses with respect to a CNO-
treated DIO-hMD3q control group of animals. Third, in vivo LFP recordings and microdialysis studies 
provide evidence of neural responses and extracellular 5-HT release in hM3Dq/Pet1-Cre, but not in 
DIO-M3Dq control animals. Finally, consistent with the notion of “subthreshold clozapine exposure” 
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(Gomez et al., 2017), the measured peak clozapine concentration is ~ 25-fold lower the exposure 
required to obtain behaviourally-relevant responses in rodents (Olsen et al., 2008), and below the 
range of values previously associated with detectable brain exposure in pharmacokinetic studies 
(Volpicelli et al., 1993). Taken together, these findings strongly argue against a contribution of 
unspecific clozapine-related effects to the signals mapped with our approach. 
Our results provide a novel reference framework for the interpretation of fMRI imaging 
studies employing 5-HT-targeting agents. In this respect, the divergent functional effects observed 
with chemogenetic stimulation and 5-HT reuptake inhibition are especially relevant, as they suggest 
that endogenous versus systemic 5-HT level boosting can lead to opposing hemodynamic 
responses, a factor that needs to be taken into account when hemodynamic readouts are used as 
surrogates for 5-HT induced neural manipulations. 5-HT is a key mediator of central and peripheral 
vasoactivity, with predominant evidence of a vasoconstrictive action via 5-HT1A, 5-HT1B and 5-HT2A 
receptors located in brain and peripheral vascular cells (reviewed by Cohen et al., 1996). Because 5-
HT reuptake inhibition rapidly increases circulating levels of this neurotransmitter (Blardi et al., 
2005, Zolkowska et al., 2008), and systemic 5-HT administration produces endothelial 
vasoconstriction (Toda and Fujita, 1973, Cohen et al., 1996), citalopram-induced rCBV decreases 
could reflect a contribution of direct vasoactive effect of circulating 5-HT on cerebral vasculature. 
Non-vascular mechanisms could also be involved in this effect, such as a possible engagement of 
different receptorial populations as a function of 5-HT release site, a hypothesis consistent with the 
wide variety in the anatomical and cellular distribution patterns exhibited by the 5-HT receptors 
subtypes so far identified (Lesch and Waider, 2012).  
While reduced cerebral blood flow in humans and rats has been reported upon citalopram 
administration (McBean et al., 1999, Geday et al., 2005), prior blood oxygen level-dependent 
(BOLD) fMRI mapping of citalopram in rats revealed increased cortical responses (Sekar et al., 
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2011). A number of methodological discrepancies could account for this result, the use of deeper 
anesthesia levels by Sekar et al., as well as the use of BOLD fMRI, as opposed to rCBV like in the 
present work, being the two most notable ones. In this respect, it should be emphasized that CBV is 
a direct and reliable indicator of microvascular activity that appears to be more directly related to 
underlying neuronal activity than BOLD fMRI (Schridde et al., 2008). Further opto- or chemogenetic 
fMRI mapping of 5-HT function employing BOLD fMRI could help conciliate these experimental 
discrepancies.  
The results of our microdialysis and LFP recordings, plus the observation of c-Fos induction 
in many regions exhibiting significant chemo-fMRI activation argue against a significant interference 
of anesthesia on our functional mapping, and support a neural origin of the mapped signals. Not 
surprisingly, discrepancies between imaging and c-Fos mapping were noted, for example in cortical 
regions or in the cerebellum. Such differences are not surprising given the diverse neuro-
physiological mechanisms underlying these two experimental readouts, and previous evidence 
showing that c-Fos induction does not always correspond to activation shown by metabolic or 
hemodynamic-based brain mapping (Stark et al., 2006, Gozzi et al., 2012, Gass et al., 1997). Indeed, 
hemodynamic responses are generally thought to reflect local synaptic input (Logothetis et al., 
2001), whereas the c-Fos protein induction is an indirect marker of cellular activation that is not 
elicited in all CNS cell and that can be affected by the behavioral state of the animal (Cirelli and 
Tononi, 2000). 
From a methodological standpoint, this work paves the way to the combined use of 
chemogenetic and fMRI to unravel the large-scale substrates modulated by pan-neuronal 
populations in the living mouse brain. Our approach follows analogous attempts to combine 
chemogenetics with non-invasive mouse brain imaging (Urban et al., 2016). Our data demonstrate 
that properly-controlled chemogenetic-fMRI studies can elicit large and sustained functional 
14 
 
responses that exhibit neuronal specificity, and can be employed to obtain to non-invasively map 
the brainwide effect of regional neural manipulations. This approach crucially complements current 
opto-fMRI simulations (Lee et al., 2010) by permitting brainwide functional mapping without the 
need of invasive cranial probes, and devoid of the confounding contribution of heat-induced 
vasodilation in anesthetized animals (Rungta et al., 2017). As such, chemo-fMRI appears to be 
optimally suited to the investigation of drug-like sustained modulatory stimulation/inhibition and 
for the deconstruction or manipulation of steady-state network activity via fMRI connectivity 
mapping (Gozzi and Schwarz, 2015). While here employed to study pan-neuronal 5-HT modulation, 
this approach can be straightforwardly expanded to manipulate focal circuits and neuronal 
ensembles via intersectional genetics or retrograde viral vectors. 
In conclusion, we describe the use of chemo-fMRI to map the brainwide substrates of 
modulatory transmission in the intact mammalian brain. We show that chemogenetic stimulation of 
endogenous serotonin neurons results in regionally-specific activation of a set of cortical and 
subcortical targets that serve as primary functional mediators of sustained endogenous 5-HT 
transmission. We also show that endogenous activation of serotonergic neurons and systemic 5-HT 
reuptake inhibition can produce opposing hemodynamic effects. Our findings provide a novel 
framework for understanding serotonin dependent functions, and interpreting data obtained from 
human fMRI studies of serotonin modulating agents.  
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Experimental Procedures  
Full-length experimental procedures can be found in Supplemental Information. 
Mouse line generation. The hM3Dq sequence fused with mCherry was isolated by a pAAV-hSyn-DIO-
hM3Dq construct (a kind gift From Dr. Bryan Roth) and inversely cloned into the ROSA26 locus 
(Krashes et al., 2011). PvuI-linearized pROSA26-1Sor-LA-CAG-DIO-hM3Dq-NEO-RA-DTa was 
electroporated in E14Tg2a.4 embryonic stem cells (ESCs). To enable the expression of hM3Dq in 5-
HT producing neurons, mice were then crossed with Pet1210-Cre mice (Pelosi et al., 2014).  
Immunohistochemical analyses and cell counting. Free floating sections were incubated at 4°C 
overnight with rabbit anti-RFP (ab62341, Abcam, 1:500) and goat anti-Tph2 (ab121020, Abcam, 
1:800). Sections were then incubated with donkey anti-rabbit (Rhodamine Red, Invitrogen, 1:500) 
and anti-goat (Alexa Fluor 488, Invitrogen, 1:500). c-Fos mapping was carried out as using a goat 
anti-cFos (SC-52-G, Santa Cruz Biotechnology, 1:1000) in a 5% horse inactivated serum solution. 
Sections were then incubated overnight at 4°C with donkey anti-goat (Alexa Fluor 488, Invitrogen, 
1:500).  
Brain Slice Electrophysiology. Brains of hM3Dq/Pet1-Cre were sectioned to obtain 300 μm coronal 
slices encompassing the dorsal raphe nucleus. Whole-cell patch clamp experiments were 
performed using borosilicate electrodes to patch DRN cells. After 5 minutes of stable baseline, CNO 
(10 μM) was bath applied for 10 minutes while recording changes in membrane potential.  
fMRI. Animal preparation for fMRI has been previously described (Ferrari et al., 2012). All drugs 
were administered intravenously. fMRI data were acquired on a 7T Pharmascan using 
intrapulmonary halothane anaesthesia (0.8%) and analyzed as previously described (Galbusera et 
al., 2017). Images were sensitized to reflect alterations in rCBV using Molday Ion, Biopal, USA.  
In vivo electrophysiology 
16 
 
LFP recordings were performed on a separate cohort of halothane anaesthetised DIO/hM3Dq or 
hM3Dq/Pet1-Cre mice, using the same animal preparation and anesthesia employed for fMRI. 
Surgery, recordings and data analyses were carried out as previously described (Galbusera et al., 
2017).  
In vivo brain microdialysis 
Microdialysis experiments were performed as recently described (Managò et al., 2016). Mice were 
implanted with concentric dialysis probes in the dorsal hippocampus. Microdialysis experiments 
were performed upon intraperitoneal administration of CNO (2 mg/kg). Dialysate samples (20µL) 
were analyzed using HPLC apparatus and a colorimetric electrochemical detector to quantify 5-HT.  
Pharmacokinetic measurements  
Blood samples (100 µl) were collected from C57BL/6J mice at different time point (15-30-60 min), 
Plasma levels of clozapine-N-oxide, clozapine and dimethyl-clozapine were monitored on a 
ACQUITY UPLC/MS TQD system consisting of a TQD (Triple Quadrupole Detector) mass 
spectrometer equipped with an electrospray ionization interface (Olsen et al., 2008). Compounds 
were quantified by monitoring their MRM peak areas.   
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Figure 1  
Generation of hM3Dq conditional knock-in mouse line. Targeted integration of the hM3Dq construct 
in the ROSA26 genomic locus. (A, top to bottom) Wild-type organization of ROSA26 mouse genomic 
locus; hM3Dq targeting vector: green (LoxP) and blue (Lox2722) arrowheads indicate the location of 
Lox sites, yellow circles indicate FRT sites; transcriptionally inactive DIO-hM3Dq allele; 
transcriptionally active hM3Dq allele (B) Southern blot analysis of genomic DNA extracted from 
embryonic stem cells clones after HindIII digestion (hM3Dq allele=6,7 kb; wild-type allele=4,4 kb). 
(C) PCR amplification of ROSA26 locus from DNA extracted from a wild-type (3), two mutant mice (1 
and 4) and two heterozygous (2 and 5) DIO-hM3Dq mice. 
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Figure 2 
hM3Dq expression in 5-HT neurons and electrophysiological validation. (A-C) Double 
immunohistochemical assay showing (A) Tph2 and (B) mCherry expression, and (C) merged 
channels in medial and dorsal raphe nucleus (MRN and DRN, respectively) of hM3Dq/Pet1-Cre mice 
(n=4). High power magnification highlighting Tph2/mCherry co-localization (A’,B’,C’) in the DRN 
lateral wings and in MRN (A”,B”,C”). (D) Quantification of hM3Dq-expressing 5-HT neurons. (E) CNO 
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application (5 µM, purple bar) in DRN brain slices from hM3Dq/Pet1-Cre mice triggered firing 
activity in mCherry(+) 5-HT neurons (discharge rate 0.19±0.03 Hz, p = 0.003), identified by their 
electrophysiological properties (inset). CNO did not elicit activity in mCherry(-) cells (F), or in DIO-
hM3Dq control cells. (E-G) Left, image of recorded cells; middle, sample traces of recorded cell 
membrane potential; right, box plot summary of changes in discharge rate in response to CNO 
application. Scale bar, 380 μm (A-C), 150 μm (A’-C”). 
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Figure 3  
fMRI response to chemogenetic stimulation of serotonergic neurons. fMRI activation produced by 
intravenous CNO administration (0.5 mg/kg, i.v.) in hM3Dq/Pet1-Cre mice (n=20) vs CNO-treated 
DIO-hM3Dq controls (n=14). (A) Anatomical distribution of the brain regions activated in 
hM3Dq/Pet1-Cre mice (Z>2, cluster corrected at p=0.05) (B) Illustrative fMRI timecourse in the 
hippocampus, CNO was administered at time 0 (means ± SEM). (C) rCBV quantification in 
representative volumes of interest (means ± SEM, *p<0.05, **p< 0.01, corrected at q=0.05). Hp: 
hippocampus; NAc: nucleus accumbens; SS : somatosensory cortex; Th: thalamus; Hyp: 
hypothalamus; DRN: dorsal raphe nucleus; Cb: cerebellum, mPFC: prefrontal cortex. 
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Figure 4  
Brainwide fMRI response to systemic citalopram administration. (A) Anatomical distribution of the 
brain regions deactivated by citalopram (10 mg/kg) (n=7) vs. vehicle (z>1.8, cluster correction 
p=0.05) (n=10). (B) Illustrative fMRI timecourse in the prefrontal cortex (means ± SEM), citalopram 
was administered at time 0. (C) rCBV quantification in representative volumes of interest (means ± 
SEM, *p<0.05, **p< 0.01, corrected at q=0.05). Hp: hippocampus; NAc: nucleus accumbens; SS: 
somatosensory cortex; Th: thalamus; Hyp: hypothalamus; DRN: dorsal raphe nucleus; Cb: 
cerebellum, mPFC: prefrontal cortex; Cg: cingulate cortex; V1: Visual cortex; Ent: entorhinal cortex.
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Figure S1, CNO dose response, related to Figure 3 
(A) rCBV timecourse produced by intravenous CNO administration in wild-type mice. CNO was administered 
intravenously at doses of 0.5 (n=6), 1 (n=4) or 2 mg/kg (n=5). rCBV timecourses are depicted in representative volumes 
of interest (VOIs) as means ± SEM. CNO or vehicle were administered at time 0; (B) Quantification of the mean rCBV 
response elicited by CNO in representative VOIs. Data are shown as mean ± standard error of the mean.  *p<0.05, **p< 
0.01, Student t test, false discovery rate correction q=0.05. The anatomical location of volumes of interest is depicted in 
Figure S5 (panel B). Hp: hippocampus; mPFC: prefrontal cortex; DRN: dorsal raphe nucleus; NAc: nucleus accumbens; 
Th: thalamus; Hyp: hypothalamus; SS: somatosensory cortex; Cb: cerebellum. (C) Plasma exposure of CNO and its 
metabolites clozapine and N-Desmethylclozapine (NMDC) upon intravenous administration of the dose employed in 
fMRI studies (0.5 mg/kg). 
 
 
 
 
 
rC
B
V
rC
B
V
rC
B
V
rC
B
V
rC
B
V
rC
B
V
rC
B
V
m
ea
n 
rC
B
V
5-
25
 m
in
A B
C
 Figure S2, Temporal profile of mean arterial blood pressure, related to Figures 3 and 4.  
Temporal profile of mean arterial blood pressure (MABP). (Top) MABP timecourse upon vehicle (n = 5) or CNO 
administration at doses of 0.5 (n=6), 1 (n=4) or 2 mg/kg i.v. (n=5). (Middle) MABP upon CNO administration (0.5 
mg/kg i.v.) to hM3Dq/Pet1-Cre (n=20) or DIO-hM3Dq (n=14) control subjects. MABP timecourse (Bottom) upon 
vehicle (n=10) or citalopram administration at dose of 5 (n=8) or 10 mg/kg i.v. (n=7) to wild type mice. Data are plotted 
as means ± SD. Drugs and vehicle were administered at time 0. 
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Figure S3, rCBV timecourse produced by chemogenetic stimulation of 5-HT neurons, related to figure 3.  
fMRI timeseries upon intravenous CNO administration (0.5 mg/kg) to hM3Dq/Pet1-Cre (n=20) and DIO-hM3Dq 
controls (n=14) mice in representative volumes of interest. The anatomical location of volumes of interest is depicted in 
Figure S5 (panel B). Data are plotted as means ± SEM. Hp: hippocampus; mPFC: prefrontal cortex; DRN: dorsal raphe 
nucleus; NAc: nucleus accumbens; Th: thalamus; Hyp: hypothalamus; SS: somatosensory cortex; Cb: cerebellum. 
 Figure S4, Hippocampal LFP recordings, related to Figure 3 
Time course of absolute theta and gamma power in the hippocampus of hM3Dq/Pet1-Cre (n=5) and DIO-hM3Dq 
control (n=5) mice upon intravenous CNO administration (0.5 mg/kg). Recordings were carried out under halothane 
sedation to replicate the same experimental conditions of fMRI. Bars indicate the standard error of the mean of 
individual data points. Linear regressions (solid lines) show a significant difference in absolute power change across the 
whole time window (***p <0.001). 
  
  
Figure S5, rCBV response to intraperitoneal CNO in wild-type mice, related to Figure 3 
(A) rCBV timecourse produced by intraperitoneal CNO administration in wild-type mice (2 mg/kg, n = 6, vehicle, n = 
6). rCBV timecourses are depicted in representative volumes of interest (VOIs) as means ± SEM. CNO or vehicle were 
administered at time 0; (B) Volumes of interest used for rCBV quantification. Hp: hippocampus; mPFC: prefrontal 
cortex; DRN: dorsal raphe nucleus; NAc: nucleus accumbens; Hyp: hypothalamus; SS: somatosensory cortex. (C) 
Quantification of the mean rCBV response elicited by CNO in representative VOIs. Data are show as mean ± standard 
error of the mean. No comparison was statistically significant (p> 0.26 all VOIS, Student t test). 
M
ea
n 
rC
B
V
10
-2
7 
m
in
Cb
SS
HypoTh
HP
Th
SS
Hypo
NAc
mPFC
DRN
HP
DRN
mPFC
SS
A B
C
 Figure S6, c-Fos induction and extracellular 5-HT release produced by hM3Dq activation of 5-HT neurons, 
related to Figure 3 
Regional c-Fos immunofluorescence in the brain of hM3Dq/Pet1-Cre mice (n=5) and control (DIO-hM3Dq, n=5) 
subjects treated with CNO (2 mg/kg, i.p.). (A-E) c-Fos induction produced by hM3Dq-mediated activation of 5-HT 
neurons. (A-D) Distribution of c-Fos-positive (green) cells (A, A’) in the hippocampus and (B, B’) nucleus accumbens 
of hM3Dq/Pet1-Cre and control mice (C, C’, D, D’). (E) Quantification of c-Fos-positive cells in the regions of interest 
(*p<0.05, **p< 0.01, Student t test, false discovery rate correction q=0.05). CA1: Cornu Ammonis 1; DG: dentate 
gyrus; AcbS: nucleus accumbens shell; ACo: anterior commissure; Hp: hippocampus; NAc: nucleus accumbens; SS: 
somatosensory cortex; Th: thalamus; Hyp: hypothalamus; DRN: dorsal raphe nucleus; Cb: cerebellum; mPFC: 
prefrontal cortex. Scale bar, Scale bar, 250 μm (A-D), 60 μm (A’-D’). (F) Extracellular serotonin release in dorsal 
hippocampus of hM3Dq/Pet1-Cre (n=6) and control DIO-hM3Dq mice (n=6) upon intraperitoneal administration of 
CNO (2 mg/kg i.p., injection at time 0, means ± SEM) in freely-behaving animals (*p< 0.05, two-way ANOVA). 
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Figure S7, rCBV timecourse produced by intravenous citalopram administration in wild-type mice, related to 
Figure 4. 
rCBV timecourse  produced by intravenous citalopram administration in wild-type mice. Citalopram was administered 
at a dose of 5 (n=8) or 10 mg/kg i.v. (n=7) at time 0. The anatomical location of volumes of interest is depicted in 
Figure S5 (panel B). Data are shown as means ± SEM.  Hp: hippocampus; mPFC: prefrontal cortex; DRN: dorsal raphe 
nucleus; NAc: nucleus accumbens; Th: thalamus; Hyp: hypothalamus; SS: somatosensory cortex; Cb: cerebellum. 
  
Supplemental Experimental Procedures  
Ethical statement. All research involving animals were carried out in accordance with the European directive 
86/609/EEC governing animal welfare and protection, acknowledged by the Italian Legislative Decree no. 116, 27 
January 1992. Animal research protocols were also reviewed and consented to by a local animal care committee.  
Mouse line generation. To enable stable and reproducible pan-neuronal stimulation of 5-HT producing cells, we first 
generated a conditional knock-in hM3Dq mouse line. The hM3Dq sequence in-frame-fused with the mCherry reporter 
and flanked by two couples of Lox sites (LoxP and Lox2722, DIO-hM3Dq, Double-floxed Inverse ORF) was isolated by 
EcoRI digestion from pAAV-hSyn-DIO-hM3Dq construct (a kind gift From Dr. Bryan Roth) and inversely cloned 
downstream to the CAG promoter in the pCX-CAG-eGFP plasmid, thus replacing the eGFP coding sequence 
(CDS)(Krashes et al., 2011). The CAG-DIO-hM3Dq fragment was extracted from the pCX-CAG-hM3Dq by a SpeI/XbaI 
double digestion and cloned into the unique XbaI site placed (Krashes et al., 2011) between the right (RA) and the left 
(LA) ROSA26 homology arms included in the pROSA26-1Sor plasmid. Pgk-Neo/Kana (NEO) and Pgk-Difteric Toxin A 
cassettes (DTA) were used for positive and negative selection, respectively. PvuI-linearized pROSA26-1Sor-LA-CAG-
DIO-hM3Dq-NEO-RA-DTa was electroporated in E14Tg2a.4 embryonic stem cells (ESCs) as previously described 
(Pelosi et al., 2015). Positive recombinants identified by southern blot were microinjected in the host C57BL/6J 
blastocysts, which were injected in utero of pseudopregnant CD1 females (3.5 dpc) to give rise to chimeras (n=29). 
Animals were routinely genotyped by PCR DNA amplification with specific oligonucleotides as primers: 5’-
GAGGGGAGTGTTGCAATACC-3’ as forward, and 5’-AGTCTAACTCGCGACACTGTA-3’ as reverse, for the wild-
type ROSA26 allele; the alternative reverse 5’-GTCCCTATTGGCGTTACTATG-3’ for the DIO-hM3Dq allele; 5’-
GTCATCTCCTTTGTCCTTTGG-3’ as forward and 5’-GGAGCTGGGTTTCCAGCTC-3’ as reverse for the hM3Dq 
CDS. Before chemo-fMRI experiments, animals were backcrossed on C57BL/6J for a least six generations. To enable 
the expression of hM3Dq in 5-HT producing neurons, mice were then crossed with Pet1210-Cre mice (Pelosi et al., 2014, 
Barrett et al., 2016). The resulting hM3Dq+/-/Pet1-Cre mice were image during young adulthood (12-20 weeks). Control 
studies with CNO and citalopram were carried out using male adult (12-20 weeks) C57BL/6J mice. 
Immunohistochemical analyses and cell counting. Mice were deeply anesthetized with avertin 1.25 % and perfused 
transcardially with 4% paraformaldehyde. Brains were dissected, post-fixed overnight in 4% paraformaldehyde at 4°C 
and sectioned in slices 50 µM thick by a Leica Microsystems vibratome. In mCherry and Tph2 immunodetection studies, 
free floating sections were incubated at 4°C overnight with rabbit anti-RFP (ab62341, Abcam, 1:500) and goat anti-Tph2 
(ab121020, Abcam, 1:800). Sections were then incubated overnight at 4°C with donkey anti-rabbit (Rhodamine Red, 
Invitrogen, 1:500) and donkey anti-goat (Alexa Fluor 488, Invitrogen, 1:500). Single and double immunolabelling was 
carried out on 4 animals encompassing a total number of cells > 4600 cells. Animals employed for c-Fos mapping (study 
#4, described below) were euthanized ninety minutes after CNO administration and processed as described above for 
immunohistochemical mapping. Free-floating sections were incubated overnight at room temperature with goat anti-cFos 
(SC-52-G, Santa Cruz Biotechnology, 1:1000) in a 5% horse inactivated serum solution. Sections were then incubated 
overnight at 4°C with donkey anti-goat (Alexa Fluor 488, Invitrogen, 1:500). Serial immunostained coronal brain sections 
were imaged using a Nikon A1 confocal microscope with a 10X or 40X objective. Cell counts analysis was performed 
using FIJI-ImageJ using the cell-counter tool (https://imagej.net/Cell_Counter). All pictures were randomized before cell 
counting, and the operator who performed the analysis (SM) was blinded to genotype and treatment. 
Brain Slice Electrophysiology. Brains of hM3Dq+/-/Pet1-Cre were sectioned to obtain 300 μm coronal slices 
encompassing the dorsal raphe nucleus. Slices were submerged in normal, oxygenated aCSF (28-30° C, 2mL/min flow 
rate) for at least 30 minutes before performing whole-cell patch clamp experiments. Borosilicate electrodes with a pipette 
filled with internal solution (135 KMeSO4, 10 KCl, 10 HEPES, 1 MgCl2, 2 Na2-ATP, 0.4 Na3-GTP (pH 7.2-7.3, 280-290 
mOsm/kg). were used to patch cells in the DRN. Signals were acquired using a Multiclamp 700B amplifier and analyzed 
with Clampfit 10.3 software (Molecular Devices, Sunnyvale, CA, USA). The effects of CNO were determined in current 
clamp mode. After 5 minutes of stable baseline, CNO (10 μM) was bath applied for 10 minutes while recording changes 
in membrane potential. For excitability experiments, the current threshold (rheobase) necessary to induce cell firing were 
determined in current clamp mode using a current ramp protocol from 0 to 100 pA. Next, a 10 pA current step protocol 
from 0 to 200 pA was applied, from which V-I plots were determined (i.e., the number of action potentials vs. current). 
We confirmed serotonergic identity of patched cells based on their intrinsic electrophysiological properties including lack 
of time-dependent depolarization in response to hyperpolarizing current pulses (Calizo et al., 2011). 
Drug formulation and pharmacological treatments  
fMRI experiments were performed using intravenous drug administration. We chose this route of administration to 
maximize the rate of fMRI signal change, with the aim to induce sharp fMRI responses that can be more easily 
discriminated from linear alterations in baseline due to scanner, contrast agent elimination or physiological drifts. 
Clozapine-n-Oxide (Sigma Aldrich) was dissolved in saline solution at a concentration of 0,125 μg/ml. The CNO dose 
employed for chemo-fMRI mapping (0,5 mg/kg i.v., volume 10 mL/kg) was selected out of dose-response experiments 
(0,5-1-2 mg/kg i.v.) described in the result section (Fig. S1). 
Pilot c-Fos mapping studies in which we used intravenous vehicle administration, showed that the prolonged restriction 
required for intravenous dosing results in broad unspecific Fos increases with respect to baseline conditions. Because the 
pharmacokinetic properties of CNO in the mouse have not been described in detail, to account for the reduced 
bioavailability and lower peak plasma concentrations often associated with intraperitoneal drug dosing (Nemes et al., 
2000, Meyer et al., 2008), we empirically adjusted CNO dosing to be used in conscious studies to 2 mg/kg. This decision 
was also motivated by a pilot fMRI study showing that intraperitoneal dosing of CNO at 2 mg/kg does not substantially 
alter fMRI baseline signal (Fig. S5; p> 0.26 all regions, Student t test, Z>1.6, statistical maps). This dose employed is in 
line with the amounts of CNO tested by other investigators in DREADD-based studies (Roth, 2016). 
Citalopram (Sigma Aldrich) was dissolved in saline solution at a concentration of 3 or 1.5 ml/kg for 10 mg/kg and 5 
mg/kg dosing, respectively. The citalopram doses tested were previously shown to be behaviorally effective in C57Bl/6J 
mice (Browne and Fletcher, 2016). 
Functional Magnetic Resonance Imaging (fMRI). Animal preparation for functional magnetic resonance imaging has 
been previously described in great detail (Ferrari et al., 2012). The protocol utilized is optimized for physiological stability 
and permits monitoring of peripheral parameters critical to the success of pharmacological fMRI (phMRI), such as 
peripheral blood pressure (Ferrari et al., 2012) and arterial blood gases. Briefly, mice were anaesthetized with isoflurane 
(5% induction), intubated and artificially ventilated (2.5% surgery). The left femoral artery was cannulated for continuous 
blood pressure monitoring and blood sampling. Surgical sites were infiltrated with tetracaine, a non-brain-penetrant local 
anesthetic (Ferrari et al., 2010).  At the end of surgery, the animal was placed in supine position onto a water-heated 
custom cradle and isoflurane was discontinued and replaced by halothane (0.8%), an anesthetic that preserves cerebral 
blood flow auto-regulation and neurovascular coupling (Gozzi et al., 2007). Functional data acquisition started 30 minutes 
after isoflurane cessation. Ventilation parameters were adjusted to maintain arterial paCO2 levels < 40 mmHg (Pepelko 
and Dixon, 1975) and paO2 levels > 90 mmHg, values which correspond to the 98% of hemoglobin saturation 
(Supplemental table I).  
fMRI data were acquired as previously described (Squillace et al., 2014) on a 7T Pharmascan (Bruker, Ettlingen, 
Germany) by using a 72-mm birdcage resonator and a 4 channel anatomical shaped Bruker mouse brain coil, placed 
dorsally to the animal head. Co-centered anatomical and fMRI images were acquired using a Rapid Acquisition 
Relaxation-Enhanced and a Fast Low-Angle Shot MRI sequence (TReff = 394.7 ms, TEeff = 3.1 ms, α=30°; 180 x 180 x 
600 µm resolution, dt = 60 s, Nr = 60 corresponding to 60 min total acquisition time). Images were sensitized to reflect 
alterations in relative cerebral blood volume (rCBV) by previous administration of 5 µl/g of blood-pool contrast agent 
(Molday Ion, Biopal, Worcester, MA, USA). Twenty-five minutes later each subject received an intravenous 
administration of vehicle or drug. fMRI responses were mapped and quantified as previously described (Galbusera et al., 
2017). Briefly, fMRI time series were spatially normalized to a common reference space and signal intensity changes 
were converted into fractional rCBV changes. rCBV time series before and after drug or vehicle injections were extracted 
and analyzed. Voxel-wise group statistics was performed using FEAT Version 5.63, with 0.5 mm spatial smoothing and 
using a boxcar input function that captured the main alterations in rCBV signal observed upon pharmacological challenge 
with respect to vehicle baseline in representative volumes of interest (Figure S1). Specifically, the chemo-fMRI response 
to 5-HT stimulation was used using a boxcar function covering a 10-28 min post-injection time window, while citalopram 
was mapped using a boxcar regressor depicting a 0-25 min post injection time window.  
The composition of experimental groups was as follows: 
Study 1: – CNO dose-response in C57Bl6J mice: intravenous treatment with CNO (0,5 mg/kg n=6; 1 mg/kg n=4; 2 mg/kg 
n=5) or vehicle (n=6).  
Study 2: Chemo-fMRI of 5-HT neurons: intravenous treatment with CNO in hM3Dq/Pet1-Cre (n = 20), or control 
DIO/hM3Dq (n = 14).  
Study 3: fMRI of citalopram in C57Bl6J mice: intravenous injection of citalopram (5 mg/kg n=8; 10 mg/kg n=7) or 
vehicle (n=10). 
Study 4: CNO-induced cFos-mapping in hM3Dq/Pet1-Cre (n = 5) or control DIO/hM3Dq mice (n = 5).  
Study 5: fMRI of intraperitoneal CNO in C57Bl6J mice: intraperitoneal treatment with CNO (2 mg/kg n=6) or vehicle 
(n=6) 
In vivo electrophysiology 
To corroborate a neural origin of the fMRI signal, acute Local Field Potential measurements were performed on a separate 
cohort of anaesthetised DIO/hM3Dq (n=5) or hM3Dq/Pet1-Cre (n=4) mice, using the same animal preparation and 
anaesthetic regimen (halothane 0.8%) employed for fMRI. Surgery and recordings were performed on a standard 
stereotaxic apparatus as previously described (Mahmud et al., 2011, Galbusera et al., 2017). A glass micropipette 
(impedance ~2 MΩ, filled with ACSF solution) was positioned in the hippocampus using the following stereotaxic 
coordinates, 1.5 mm ML, 2.2 mm AP and 1.3 mm DV, corresponding to the location of brain microdialysis probe. A 
common reference Ag-AgCl electrode was placed on the cortical surface. Electrophysiological signals were amplified 
1000-fold (EXT-02F, NPI), band pass filtered (0.1–1000 Hz), and sampled at 5 kHz with 16 bit precision by a National 
Instruments (NI-usb6251) AD board controlled by custom made LabView software. Line frequency 50 Hz noise was 
removed by means of a linear noise eliminator (Humbug, Quest Scientific). LFP activity was recorded over a 18 minute 
time window before CNO and 1 hour after intravenous administration of CNO (0.5 mg/kg i.v.). Spectral analysis was 
performed on Theta (6 < Hz < 12) and Gamma bands (30 < Hz < 80 Hz). Two consecutive temporal points were binned 
together to reduced data dimensionality. Intergroup differences were assessed using a slope analysis after linear regression 
as summary statistics over the whole examined time window as recently described (Galbusera et al., 2017) using 
GraphPad Prism (GraphPad Software, Inc.).  
In vivo brain microdialysis 
Microdialysis experiments were performed as recently described (Managò et al., 2016). Briefly, male two-month old 
hM3Dq/Pet1-Cre mice (n=6) and control DIO/hM3Dq mice (n=6) were anesthetized with Isoflurane and then placed in 
a stereotaxic frame (2B, 2biological instruments) for probe implantation. Concentric dialysis probes were prepared using 
AN69 dialyzing membranes (Hospal Dasco, Bologna, Italy). Probes were implanted in the dorsal hippocampus using the 
same coordinates employed for LFP studies. Microdialysis test sessions were performed during the light phase prior to 
and after intraperitoneal administration of CNO (2 mg/kg). Probes were connected to PE50 tubes and perfused with 
Ringer’s solution (147.0 mM NaCl, 2.2mM CaCl2, and 4.0 mM KCl) delivered by a 1.0 ml syringe, operated by a BAS 
Bee Syringe Pump Controller (BAS West Lafayette, IN, USA), through the dialysis probes at a constant flow rate of 1 
µL/min. Dialysate samples (20µL) were analyzed using HPLC apparatus equipped with a reverse-phase column (C83.5 
µm, Waters, USA) and a coulometric electrochemical detector (ESA Coulochem II, Bedford, USA) to quantify 5-HT. 
The electrodes of the analytical cell were set at – 175 mV (oxidation) and  +220 mV (reduction). The composition of 
mobile phase was: 50 mM NaH2PO4, 0.1 mM Na2EDTA, 0.5 mM n-octylsulfate and 22% (v/v) methanol, pH 5.7. The 
sensitivity of the assay for 5-HT was 5 fmol/sample. At the end of each experiment, mice were sacrificed and their brains 
were removed and stored in formalin (4%) before histological analysis. Brain were cut in serial coronal slices (100 µm) 
to locate the placement of the microdialysis probe. All the numerical data are given as mean ± SEM. Data were analyzed 
by utilizing two-way repeated measures ANOVA.  
Pharmacokinetic measurements  
Blood samples (100 µl) were collected from 10 male adult (12-20 weeks) C57BL/6J mice at different time point (15-30-
60 min). Animal preparation was carried out as previously described for fMRI acquisition, to allow for intravenous 
administration of CNO (0.5 mg/Kg) under halothane sedation (0.8%). All solvents and chemicals were purchased from 
Sigma Aldrich (Milano, Italia). Plasma samples were centrifuged for 20 min. A 50 µl aliquot was then transferred into a 
96-deepwell plate and added with 150 µl of the extraction solution, consisting of cold acetonitrile spiked with clozapine-
d4 as internal standard. After agitation (3 minutes) the plate was centrifuged at 3000g for 20 minutes at 4°C. 80 µl of 
supernatant were then transferred in a 96-well plate and added with 80 µl of water. Reference standards of clozapine-N-
oxide, clozapine and dimethyl-clozapine were spiked in naïve mouse plasma to prepare a calibration curve over the 1 nM 
– 10 µM range. Three quality controls samples were also prepared by spiking the compounds in blank mouse plasma to 
final 20, 200 and 2000 nM concentrations. Calibrators and QCs were extracted with the same extraction solution used for 
the plasma samples. Plasma levels of clozapine-N-oxide, clozapine and dimethyl-clozapine were monitored on a 
ACQUITY UPLC/MS TQD system consisting of a TQD (Triple Quadrupole Detector) mass spectrometer equipped with 
an electrospray ionization interface; 3ul of each sample were injected on a reversed phase column (Acquity UPLC BEH 
C18 2.1 X 50 mm, 1.7  m particle size) and separated with a gradient of acetonitrile (10% to 50% B in two minutes). 
Column and UPLC-MS system were purchased from Waters Inc. Milford, USA. Flow rate was set 0.5mL/min. Eluents 
were A = water and B = acetonitrile, both added with 0.1% formic acid. Analysis was performed in ESI+ ionization mode. 
Compounds were quantified by monitoring their MRM peak areas. The following parameters were used for analyte 
detection and quantification: 
Analyte 
Retention Time  
(minutes) 
Precursor 
m/z 
Fragment 
m/z 
Cone 
voltage (V) 
Collision 
energy (eV) 
clozapine-N-oxide 1.87 
343 227 30 35 
343 243 30 35 
343 256 35 25 
clozapine 1.70 327 227 45 40 
327 270 45 30 
327 296 45 30 
demethyl-clozapine 1.57 
313 192 45 45 
313 227 45 35 
313 270 45 30 
clozapine-d4 (internal 
standard) 
1.70 
331 272 45 30 
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Supplemental Information Inventory  
Supplemental data items 
Figure S1, CNO dose response, related to Figure 2. 
Figure S2, Temporal profile of mean arterial blood pressure, related to Figure 3 and 4. 
Figure S3, rCBV timecourse produced by chemogenetic stimulation of 5-HT neurons, related to figure 3. 
Figure S4, Hippocampal LFP recordings, related to Figure 3 
Figure S5, rCBV response to intraperitoneal CNO in wild-type mice, related to Figure 3 
Figure S6, c-Fos induction and extracellular 5-HT release produced by hM3Dq activation of 5-HT neurons, related to 
Figure 3 
Figure S7, rCBV timecourse produced by intravenous citalopram administration in wild-type mice, related to Figure 4. 
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